DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | SGLT2 Inhibitors